Interstitial lung diseases
State of the art sessionChairs: K. Antoniou (Heraklion, Greece), K. Moor (Rotterdam, Netherlands), S. Harari (Milano (MI), Italy)
Aims: to present significant insights gained recently about many different forms of rare lung diseases, i.e cystic lung diseases (lymphangioleiomyomatosis), fibrosing lung diseases. To discuss new treatment options that have been licensed for different pulmonary complications of autoimmune diseases, which commonly affect the lungs; to provide an update about drug-induced lung diseases that are an important differential diagnosis of ILDs; to discuss challenges in diagnosis and treatment. to emphasize the importance of acute exacerbations which are one of the most debilitating complications of mainly fibrosing ILDs and are a neglected field.